Inductively coupled plasma with mass-spectrometry method development and validation for gadolinium in gadolinium-based contrast agents of pharmaceutical formulations
1
Citation
3
Reference
10
Related Paper
Citation Trend
Abstract:
Gadolinium-based contrast agent interacts with the human body temporarily and improves the pictures of inside of the body produced by magnetic resonance imaging, computed tomography, X-rays and ultrasound and it also helps to distinguish the normal from abnormal conditions. In this study, the authors developed a simple, rapid, reliable and robust inductively coupled plasma mass-spectrometry method for estimation of gadolinium in gadolinium-based contrast agents to check the drug quality and ensure the patient safety. The samples were digested at 160°C using the microwave digestion system and the gadolinium was extracted in 0.4% (w/w) nitric acid. Interference of deposited gadolinium on sample cone and skimmer cone were investigated and evaluated. The developed method was validated as per ICH Q2 (R1) guideline and USP<730>. The precision was evaluated with six independent assays of gadolinium in each gadolinium-based contrast agent. The test method was found linear (r2 > 0.999) with five different levels covered from 25~200%, and accurate, mean recoveries were 92.5~107.5% at three different levels covered from 50~150%. The robustness was performed by changing the nitric acid concentration (0.4±0.04%, w/w) in diluent system. This method is suitable to quantitatively determine the amount of gadolinium in gadolinium-based contrast agent of drug products in presence of excipients used in formulation and also in drug substance.Keywords:
MRI contrast agent
MRI contrast agent
Cite
Citations (0)
Sulfonamide
MRI contrast agent
Biodistribution
Cite
Citations (17)
Gadolinium diethylenetriaminepentaacetic di[5-(4'-amidophenyl)-10,15,20- tris(4'-sulfonatophenyl) porphyrin trisodium salt] (Gd-DTPA-2APTSPP) was synthesized by the reaction of diethylenetriaminepentaacetic dianhydride with 5-(4'-aminophenyl)-10,15,20-tris(4'-sulfonatophenyl) porphyrin and subsequently chelation with gadolium chloride.This gadolinium complex was characterized and its properties in vitro and in vivo were also evaluated. Compared with Gd-DTPA, Gd-DTPA-2APTSPP possessed high relaxivity r1, low cytotoxicity to HeLa cells and high enhanced signal intensities of the VX2 carcinoma in rabbits for a prolonged time.Moreover, Gd-DTPA-2APTSPP can distinguish the VX2 carcinoma from the reactive hyperplasia incited by inflammation and normal tissues in rabbits. Therefore, Gd-DTPA-2APTSPP can be taken up selectively by tumors and show the potential as a tumor-targeting MRI contrast agent.
Cite
Citations (6)
Water-soluble gadolinium (Gd) endohedral metallofullerenes have been synthesized as polyhydroxyl forms (Gd@C(82)(OH)(n)(), Gd-fullerenols) and their paramagnetic properties were evaluated by in vivo as well as in vitro for the novel magnetic resonance imaging (MRI) contrast agents for next generation. The in vitro water proton relaxivity, R(1) (the effect on 1/T(1)), of Gd-fullerenols is significantly higher (20-folds) than that of the commercial MRI contrast agent, Magnevist (gadolinium-diethylenetriaminepentaacetic acid, Gd-DTPA) at 1.0 T close to the common field of clinical MRI. This unusually high proton relaxivity of Gd-fullerenols leads to the highest signal enhancement at extremely lower Gd concentration in MRI studies. The strong signal was confirmed in vivo MRI at lung, liver, spleen, and kidney of CDF1 mice after i.v. administration of Gd-fullerenols at a dose of 5 micromol Gd/kg, which was 1/20 of the typical clinical dose (100 micromol Gd/kg) of Gd-DTPA.
MRI contrast agent
Nephrogenic Systemic Fibrosis
Cite
Citations (457)
MRI contrast agent
Renal physiology
Bovine serum albumin
Cite
Citations (50)
Conventional low molecular weight gadolinium based Magnetic Resonance Imaging (MRI) contrast agents such as Magnevist® are very useful for imaging tissues. However, at the high magnetic fields used in modern MRI equipments, their relaxivity (contrasting efficiency) is rather poor. The grafting of the gadolinium complex onto macromolecules is a way to enhance their relaxivity provided that the rotational motion of the complex is decreased significantly. Here we report the design of novel Gd3+ based MRI contrast agents with improved relaxivity and potential long blood circulation life-time. We investigate the grafting of 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, 1,4,7-tris(1,1-dimethylethyl) ester (DO3AtBu-NH2; a precursor of Gd3+ ligand) onto well-defined functional copolymers bearing activated esters (succinimidyl esters) and poly(ethylene oxide) (PEO) chains required for stealthiness. The tert-butyl groups of grafted DO3AtBu-NH2 are then deprotected by trifluoroacetic acid followed by complexation of Gd3+. Addition of free DOTA at the end of the reaction is necessary to leave the pure and stable water soluble macrocontrast agent. Importantly it shows a relaxivity at high frequencies that is 300% higher than that of the ungrafted gadolinium complex. These novel functional copolymers are therefore promising candidates as macromolecular contrast agents for MRI applications.
DOTA
MRI contrast agent
Trifluoroacetic acid
Tetramine
Cite
Citations (31)
MRI contrast agent
Human serum albumin
Cite
Citations (26)
MRI contrast agent
Cite
Citations (12)
To synthesize block copolymer-based gadolinium nanoparticles (Gd-NPs) and evaluate their potential as a new MRI contrast agent.The Gd-NPs were developed through coordination of gadolinium chelates into a pentablock copolymer synthesized by two sequential atom transfer radical polymerizations, and evaluated by measuring their T1 relaxivity in vitro and imaging their T1 contrast in tissue using MRI.Solution and MRI studies demonstrated that these Gd-NPs exhibit remarkably high T1 relaxivity on both per particle and per gadolinium ion basis, and can generate a much better MRI contrast compared with gadolinium chelates alone.These novel Gd-NPs may have important applications in magnetic resonance-based medical imaging.
MRI contrast agent
Cite
Citations (18)
Oligonucleotide modified gadolinium phosphate nanoparticles have been prepared and their magnetic resonance relaxivity properties measured. Nanoparticles of GdPO4·H2O were synthesized in a water/oil microemulsion using IGEPAL CO-520 as surfactant, resulting in 50 to 100 nm particles that are highly dispersible and stable in water. Using surface modification chemistry previously established for zirconium phosphonate surfaces, the particles are directly modified with 5′-phosphate terminated oligonucleotides, and the specific interaction of the divalent phosphate with Gd3+ sites at the surface is demonstrated. The ability of the modified nanoparticles to act as MRI contrast agents was determined by performing MR relaxivity measurements at 14.1 T. Solutions of nanopure water, Feridex, and Omniscan (FDA approved contrast agents) in 0.25% agarose were used for comparison and control purposes. MRI data confirm that GdPO4·H2O nanoparticles have relaxivities (r1, r2) comparable to those of commercially available contrast agents. In addition, the data suggest that biofunctionalization of the surface of the nanoparticles does not prevent their function as MRI contrast agents.
MRI contrast agent
Surface Modification
Cite
Citations (54)